Lee, Seohyuk
Ma, Chao
Shi, Qian
Meyers, Jeffrey
Kumar, Pankaj
Couture, Felix
Kuebler, Philip
Krishnamurthi, Smitha
Lewis, DeQuincy
Tan, Benjamin
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
Shields, Anthony F.
Meyerhardt, Jeffrey A. http://orcid.org/0000-0002-1120-0898
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10CA180821, U10CA180882, U10CA180868, UG1CA233234, U10CA180820, U10CA180888)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Douglas Gray Woodruff Chair fund Guo Shu Shi Fund Anonymous Family Fund for Innovations in Colorectal Cancer George Stone Family Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 2 July 2022
Revised: 13 April 2023
Accepted: 19 April 2023
First Online: 13 May 2023
Competing interests
: Dr. Shi reported receiving institutional grant support from Celgene–Bristol Myers Squibb and Roche/Genentech; serving as a consultant to Yiviva Inc and Boehringer Ingelheim Pharmaceuticals; and owning stock in Johnson & Johnson, Merck, and Amgen. Dr. Kuebler reported receiving grants from the Columbus National Community Oncology Research Program and the National Institutes of Cancer. Dr. O’Reilly reported receiving institutional grants from Genentech/Roche, Celgene/Bristol Myers Squibb, BioNTech, AstraZeneca, and Arcus; receiving personal fees from CytomX Therapeutics, Rafael Therapeutics, Sobi Consulting, and Synthorx Inc; nonfinancial support from Silenseed Consulting, consulting fees from Boehringer Ingelheim, BioNTech, Ipsen, and Merck; and his spouse receives consulting fees from Bayer, Genentech/Roche, Celgene/Bristol Myers Squibb, Eisai, and Polaris; and personal fees from Molecular Templates Consulting. Dr. Shields reported receiving grants from National Cancer Institute. Dr. Meyerhardt reported receiving grants from National Cancer Institute and personal fees for serving on the advisory boards of COTA Healthcare and Merck, and institutional support from Boston Biomedical for a clinical trial outside the submitted work. The remaining authors declare no competing interests.
: All patients signed study-specific informed consent, which was approved by the NCI Cancer Treatment Evaluation Program and each participating site’s institutional review board. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.